Onychomycosis Treatment Market in North America is expected to display a CAGR of 7% during the forecast period 2022 to 2032

In 2022, it is anticipated that the Onychomycosis Treatment Market will have a value of US$ 4.44 billion. The market for onychomycosis treatments is anticipated to grow at a CAGR of 8.46% from 2022 to 2032 and reach a value of US$ 10 billion. The market is expanding as a result of the rising incidence of diabetes, which increases the risk of nail fungal infection.

Accounting for approximately 12% of the entire fungal infection treatments space, onychomycosis treatment has been witnessing a high prevalence-low awareness scenario over the years. However, gradually increasing awareness about the potential threats of onychomycosis and growing availability of treatments for the condition clearly point to a promising outlook for onychomycosis treatment market over the course of coming years.

The roughly US$ 4.5 billion global market for onychomycosis treatment is slated to observe robust year on year revenue growth of 6.4% in 2019. A new market research study by Future Market Insights throws light on the increasing role of combination therapy recommendations in supporting demand growth of onychomycosis treatment, in the near future.

Request Sample PDF Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1279

Key Market Players considered in the Study:

• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Medimetriks Pharmaceuticals, Inc.
• Galderma
• Johnson & Johnson
• Novartis AG
• Moberg Pharma AB
• Cardinal Health, Inc.
• Pfizer Inc.
• Almirall, S.A.
• Bayer AG
• Viatris Inc.
• GlaxoSmithKline plc
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd

Growing Inclination towards Combination Therapy to Boost Nail Lacquer Sales

With bolstering recommendations for combination therapy by both podiatrists and dermatologists is cited as another strong factor encouraging the demand for onychomycosis treatment worldwide. Research indicates an increased cure rate when the treatment combines systemic and topical therapies, which is presumably stimulating onychomycosis patients to opt for treatment that involves long-term antifungal drugs medication, followed by application of nail lacquers.

Ask An Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-1279

A senior market research analyst at FMI explains, “Oral terbinafine has been a popular choice for including in the combination therapy over the years, which is followed by amorolfine nail lacquer in follow-up sessions. The emergence of more such combination therapies as a part of onychomycosis treatment is likely to support the growth of onychomycosis treatment market in coming years”.

Nearly 80% Revenue Belongs to Distal Subungal Onychomychosis Treatment

Distal subungal onychomycosis, though is the most prevalent disease indication pushing the demand for treatment with almost 80% share in the total market value, the report projects that the prevalence of proximal subungal onychomycosis would increase at a significant rate in coming years.

North America & Western Europe Bag in over 70% Market Value Share

Holding a collective revenue share of more than 70%, North American and Western European markets for onychomycosis treatment continue to provide the strongest push to market growth. In addition to the highest onychomycosis prevalence, North America’s landscape reaps a major advantage of favorable reimbursement scenario in the US.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1279

Analysis of the Moderately Consolidated Market Structure

Among the top performers in the global onychomycosis treatment landscape including Novartis AG, Galderma S.A., Valeant Pharmaceuticals, Inc., Johnson & Johnson Services, Pfizer, Inc., and others, the top five companies account for a global market share of over 43% – leaving the market as a moderately consolidated landscape. With an objective to achieve impactful product promotion campaigns, companies are signing sales and marketing agreements, according to the report.

• As indicated by recent research data, Valeant’s Jublia and Pfizer’s Diflucan have been the key brands responsible for sizable revenue generation in the onychomycosis treatment marketplace.
• Jublia continues to enjoy booming sales through the company’s D2C (direct-to-consumer) marketing strategy. Galderma’s Loceryl and Novartis’ Lamisil are also projected to retain higher attractiveness in the onychomycosis treatment landscape.
• The leading market players are likely to maintain their strategic focus on a strong sales channel and a versatile distribution network.

Use promo code >> FMITODAY to get flat 20% discount

Onychomycosis Treatment Market Segmentation Analysis:

Treatment Type:

• Drugs
  • Oral
    • Rx
    • OTC
  • Topical
    • Rx
    • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd:YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Disease Indication:

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Age Group:

• 0-18 Years
• 18-39 Years
• 40-64 Years
• 65 Years & Above

Gender:

• Male
• Female

Distribution Channel:

• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs